Phase 2 Spring Trial Of LHP588, Treatment For P. Gingivalis-positive Alzheimer ' s Disease Proceeds

SAN FRANCISCO, Nov. 16, 2023. Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of Alzheimer ' s and other diseases of aging, today announced clearance by the U.S. Food and Drug...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials